J&J’s MonumenTAL-3 Data Rewrites the Myeloma Playbook Before the Ink Dries on DPd

Picture the scene in Stockholm on June 12, when Abstract S100 landed at the European Hematology Association Congress: a 72% reduction in the risk of progression or death, a 53% reduction in the risk of dying outright, and a 24-month progression-free survival rate of 81.3% in relapsed or refractory multiple myeloma patients who had, in many cases, already burned through lenalidomide and a proteasome inhibitor. The comparator arm, daratumumab plus pomalidomide plus dexamethasone (DPd), managed a 51.2% PFS rate at the same timepoint. The data were simultaneously published in the New England Journal of Medicine. Rooms went quiet.

The clinical headline from MonumenTAL-3 is striking on its own terms. But read it as a commercial document and something more consequential emerges: Johnson & Johnson is not simply extending TALVEY’s life cycle from late-line salvage into earlier settings. It is repositioning its entire bispecific franchise to occupy the territory where treatment decisions are most consequential, most durable, and most profitable.

That ambition, if it translates into label expansion and payer acceptance, carries implications that stretch well beyond one trial.

The Geometry of the Franchise

Start with the commercial baseline. TALVEY received accelerated FDA approval on August 9, 2023, for patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. That label is commercially constrained by definition. Fourth-line-plus is a small, fragmented, and short-duration market. Patients cycle through faster, payers scrutinize cost-effectiveness more aggressively against a grim backdrop, and the commercial ceiling reflects the clinical reality: you are treating a very sick population with limited runway.

Moving from fourth-line to second-line is not an incremental label expansion. It is a franchise reconstruction. The addressable patient population multiplies, the duration of therapy lengthens, and the competitive moat deepens because earlier-line approvals tend to be stickier with prescribers. Oncologists who initiate a regimen in the second line and see deep, durable responses do not abandon it when their next RRMM patient walks in. MonumenTAL-3 enrolled 864 patients who had received at least one prior line of therapy, with 85.1% lenalidomide-refractory and 93.4% refractory to their most recent therapy. Critically, only 11.8% had prior anti-CD38 exposure, meaning this is a population that still has daratumumab-based options ahead of them, and J&J is threading talquetamab into that window.

The hazard ratios in MonumenTAL-3 are not borderline-significant. Tal-DP posted an HR of 0.28 (95% CI: 0.20-0.40, p<0.0001) for PFS versus DPd. Tal-D, the pomalidomide-free doublet arm, posted an HR of 0.33 (95% CI: 0.24-0.46, p<0.0001). Both are well below the threshold where a payer medical director starts looking for methodological objections to deny coverage. Complete response rates of 71.1% for Tal-DP and 68.9% for Tal-D, against 34.5% for DPd, and MRD-negative complete response rates of 52.3% and 46.3% against 15.9%, tell a story of qualitative depth that the PFS curves alone do not fully capture.

What the Street Is Underpricing

Here is the counterintuitive read that most commercial models are missing: the pomalidomide-free Tal-D arm may matter more strategically than the superior Tal-DP arm, even though Tal-DP has the stronger efficacy numbers.

DPd is entrenched partly because pomalidomide is a known, widely reimbursed anchor. A regimen that delivers an HR of 0.33 without pomalidomide preserves pomalidomide as a later-line option for patients who progress. That sequencing logic is extraordinarily important to oncologists managing a chronic disease like myeloma, where patients can cycle through six, seven, or eight lines of therapy over a decade. Research published in the National Library of Medicine found that among lenalidomide-refractory RRMM patients after first prior therapy, cumulative attrition reached 85%, with 60% receiving no further treatment after second-line failure. If you can achieve 77.6% PFS at 24 months without consuming pomalidomide, you are potentially buying patients access to a subsequent line of therapy they would otherwise never reach.

That argument has a dollar sign attached to it. Longer patient journeys mean more therapy lines, more duration on J&J products across the sequence, and a compelling pharmacoeconomic narrative for payers who are increasingly asked to think in episodes of care rather than single-line approvals.

MonumenTAL-3 is also the third consecutive Phase 3 positive readout from J&J’s bispecific portfolio in recent months. The MajesTEC-3 study of teclistamab plus daratumumab established BCMA-directed bispecific combination efficacy in earlier lines. MonumenTAL-3 now does the same for GPRC5D-directed talquetamab. J&J is not running two parallel programs by accident. The strategy is to build a bispecific backbone across two distinct targets so that, regardless of whether a patient’s tumor biology favors BCMA or GPRC5D engagement, the company has a franchise-level answer at every inflection point in the disease course.

A real-world prospective comparison presented at ASCO 2025, covering 266 RRMM patients without prior CAR-T exposure, found comparable efficacy between anti-BCMA and anti-GPRC5D bispecific T-cell engagers. If GPRC5D and BCMA produce similar outcomes in a head-to-head real-world comparison, then controlling both targets is a structural advantage, not redundancy. A competitor developing a single BCMA bispecific cannot offer the sequencing optionality that J&J’s dual-target portfolio can.

The Competitive Clock Is Now Running

DPd’s reign as the default second-line RRMM standard was always vulnerable; the APOLLO Phase 3 study established DPd against pomalidomide and dexamethasone alone in 304 patients, and it was a meaningful advance at the time. But APOLLO was not designed against a GPRC5D-directed bispecific. MonumenTAL-3 was. The comparator chosen for MonumenTAL-3 is specifically the regime it intends to displace, and the magnitude of benefit is large enough that any payer or guideline committee will have difficulty arguing for DPd on cost grounds alone without a survival counterargument to present. The 24-month overall survival of 89.2% for Tal-DP versus 79.1% for DPd is precisely the kind of number that gets cited in NCCN deliberations.

For BD teams at competing myeloma franchises, the MonumenTAL-3 data sharpens an already uncomfortable question about target selection. Regeneron and Sanofi’s isatuximab-based combinations, Bristol Myers Squibb’s CELMoD agents, and various BCMA-CAR-T programs are all competing for the same second-line slots. J&J now holds Phase 3-validated evidence at that line for two distinct bispecific mechanisms, with daratumumab as the common backbone. Any mid-cap or large-cap oncology program without a daratumumab-class CD38 anchor or a validated bispecific combination will feel the gravitational pull of this data set when partnering discussions open in the second half of 2026.

The GPRC5D target itself deserves attention. Unlike BCMA, GPRC5D expression is largely absent on normal B cells, which means talquetamab can engage myeloma cells while leaving healthy immune architecture more intact. That mechanistic distinction becomes commercially meaningful when you are trying to combine bispecifics with a CD38 antibody that is already doing significant immune-modulatory work. The complementary mechanism argument embedded in the MonumenTAL-3 design, where daratumumab prepares the immune environment for enhanced talquetamab activity, is not just a scientific rationale. It is a formulary defense. If the combination works because of mechanistic synergy rather than additive toxicity, the reimbursement case is structurally stronger.

Any oncology franchise planning its 2027 commercial roadmap for RRMM should be reverse-engineering its second-line positioning assumptions today. The MonumenTAL-3 data will enter regulatory submissions before year-end, and if the FDA converts accelerated approval into a full label expansion with a second-line indication, the prescribing landscape shifts faster than most commercial models are currently projecting. The hematologists who attended EHA in Stockholm already saw the data. Their patients will be asking questions on Monday morning.

That regulatory affairs director who opened the MonumenTAL-3 abstract on June 12 and saw a 72% reduction in progression risk was not reading a clinical milestone. She was reading a commercial verdict on every DPd-based regimen her competitors have built the next three years around.

References

1. Johnson & Johnson EMEA via GlobeNewswire — “MonumenTAL-3 Phase III Results: TALVEY plus daratumumab in RRMM” (June 18, 2026)
2. FDA — “FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma” (August 9, 2023)
3. Johnson & Johnson — “MajesTEC-3 Phase 3 Study Results: Teclistamab plus Daratumumab in RRMM”
4. Cancer Network — “Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma” (ASCO 2025)
5. Multiple Myeloma Hub — “APOLLO Trial Results: Addition of Daratumumab to Pomalidomide/Dexamethasone in RRMM”
6. National Library of Medicine — “Cumulative Attrition in Lenalidomide-Refractory RRMM Patients After First Prior Line of Therapy”